SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors

Trial Details

NCT ID
NCT06873659
Phase
PHASE1
Sponsor
Qurgen Inc.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • SON-DP
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Male or female participants aged 18 to 75 years (inclusive).
  • For Phase Ia: Participants with histologic diagnosis and confirmed solid tumor; For Phase Ib: Participants with one of the two tumor types: Group 1…
  • There must be at least one measurable lesion defined by RECIST v1.1. Lesions intended for biopsy should generally not be selected as target lesions…
  • The ECOG performance status ≤ 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →